Advertisement

What’s the latest on iron therapy

Quali sono le ultime novità in tema di terapia marziale

Abstract

Anemia is a common complication of chronic kidney disease (CKD) and is usually treated with erythropoiesis-stimulating agents (ESA) and iron supplementation.
Endovenous iron therapy has been recently ruled (and limited) by both the European and Italian medicines agencies due to serious, despite rare, adverse events.
A recent analysis of data from the Dialysis Outcomes and Practice Patterns Study (DOPPS) has shown an association between high endovenous iron therapy (more than 300 mg/month) and increased mortality in patients with hemoglobin levels higher than 10 g/dL.
The new molecules available on the market should have a better safety profile and several advantages related to the possibility of administering a high iron dose in a single infusion.
Iron supplementation through the dialysate and through new phosphate binders demonstrates the great scientific interest in this important field, also to the advantage of our CKD patients.

G Tec Nefrol Dial 2014; 26(3): 296 - 300

Article Type: SPECIAL FOCUS REVIEW

Article Subject: TN&D JOURNAL CLUB

DOI:10.5301/GTND.2014.12699

Authors

Andrea Cavalli, Giuseppe Pontoriero

Article History

This article is available as full text PDF.

Download any of the following attachments:

Authors

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.